» Download Public Reports
About 500 reports
- Company report
- May 2013
- 46 pages
... On applying gene therapy technology to genetically modify a patient S own t-cells, known as chimeric antigen receptor (car) t-cells, to target and destroy cancer cells. Celgene has an option to license any ...
April 2013
... Private donations Philanthropic organizations Patient advocacy groups 45 disease-focused groups step in: selected grants philanthropy company als biopharma, yuma therapeutics, metabolic solutions ...
January 2013
... At the right time) So why is a statistician talking to you about personalized medicine My goal: t o con vince y ou that the quantitativ e sciences , and especially statistics , are essential ...
December 2012
... And oxymorphone, are reimbursed by pfizer. A71 pain therapeutics retains commercial rights to remoxy and three other abuse-resistant drug cands in australia/new zealand. We have not yet announced a market ...
December 2012
... Of outpatient physical therapy services: economic benefits of therapy services. Purchasers and providers of healthcare services, such as insurance companies, health maintenance organizations, businesses ...
December 2012
... Of the primary treatment methods, including: the increased life expectancy and aging of the population, which is likely to drive an increase in the incidence of the disease as approximately 77% of all cancers ...
December 2012
... Under a wide variety of conditions, ptns remained significantly less costly than sns over two years of therapy for those patients with oab refractory to conservative and drug therapy. Melissa ...
November 2012
... Adult source of cell to be used clinically has a generally weak therapeutic signal in many of the reported studies and trials. As the field matures, companies, researches, regulators, and clinicians ...
» Purchase Premium Reports
(From $ 125 - $ 3 500)
About 1 200 reports
- $ 3 500
- Industry report
- April 2013
- by GBI Research
ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment Summary GBI Research, the leading business intelligence provider, has released its ...
April 2013
$ 3 270
Global Market Watch: The broad ?health care' division has been witnessing a rapid growth and technological improvements varying from sector to sector since the past 3-5 years. The evolution of cardiac ...
May 2013
$ 2 500
Gynecological Cancer - Pipeline Review, H1 2013 Summary Global Markets Direct's, 'Gynecological Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This ...
April 2013
$ 2 500
Psychiatric Disorders - Pipeline Review, H1 2013 Summary Global Markets Direct's, 'Psychiatric Disorders - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This ...
May 2013
$ 2 495
The focus of this report is the use of personalized medicine for pharmacological/diagnostic combinations; particularly pharmacological therapies and the diagnostic tests, which can provide information ...
May 2013
$ 2 000
Hyperuricemia - Pipeline Review, H1 2013 Summary Global Markets Direct's, 'Hyperuricemia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides ...
May 2013
$ 2 000
Ebola and Marburg Infections - Pipeline Review, H1 2013 Summary Global Markets Direct's, 'Ebola and Marburg Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic ...